Cargando…

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

PURPOSE: Application of linear‐quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi‐activation (UMA) model to fit cell survival curves over the entire dose range that allo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shidong, Miyamoto, Curtis, Wang, Bin, Giaddui, Tawfik, Micaily, Bizhan, Hollander, Andrew, Weiss, Stephanie E., Weaver, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248130/
https://www.ncbi.nlm.nih.gov/pubmed/33590493
http://dx.doi.org/10.1002/mp.14690
_version_ 1783716662219898880
author Li, Shidong
Miyamoto, Curtis
Wang, Bin
Giaddui, Tawfik
Micaily, Bizhan
Hollander, Andrew
Weiss, Stephanie E.
Weaver, Michael
author_facet Li, Shidong
Miyamoto, Curtis
Wang, Bin
Giaddui, Tawfik
Micaily, Bizhan
Hollander, Andrew
Weiss, Stephanie E.
Weaver, Michael
author_sort Li, Shidong
collection PubMed
description PURPOSE: Application of linear‐quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi‐activation (UMA) model to fit cell survival curves over the entire dose range that allows us to calculate EQD2 for hypofractionated SBRT, SRT, SRS, and HDRB. METHODS: A unified formula of cell survival [Formula: see text] using only the extrapolation number of n and the dose slope of D(o) was derived. Coefficient of determination, R(2), relative residuals, r, and relative experimental errors, e, normalized to survival fraction at each dose point, were calculated to quantify the goodness in modeling of a survival curve. Analytical solutions for α and β, the coefficients respectively describe the linear and quadratic parts of the survival curve, as well as the α/β ratio for the LQ model and EQD2 at any fractional doses were derived for tumor cells undertaking any fractionated radiation therapy. RESULTS: Our proposed model fits survival curves of in‐vivo and in‐vitro tumor cells with R(2) > 0.97 and r < e. The predicted α, β, and α/β ratio are significantly different from their values in the LQ model. Average EQD2 of 20‐Gy SRS of glioblastomas and melanomas metastatic to the brain, 10‐Gy × 5 SBRT of the lung cancer, and 7‐Gy × 5 HDRB of endometrial and cervical carcinomas are 36.7 (24.3–48.5), 114.1 (86.6–173.1),, and 45.5 (35–52.6) Gy, different from the LQ model estimates of 50.0, 90.0, and 49.6 Gy, respectively. CONCLUSION: Our UMA model validated through many tumor cell lines can fit cell survival curves over the entire dose range within their experimental errors. The unified formula theoretically indicates a common mechanism of cell inactivation and can estimate EQD2 at all dose levels.
format Online
Article
Text
id pubmed-8248130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82481302021-07-02 A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS) Li, Shidong Miyamoto, Curtis Wang, Bin Giaddui, Tawfik Micaily, Bizhan Hollander, Andrew Weiss, Stephanie E. Weaver, Michael Med Phys BIOLOGICAL PHYSICS AND RESPONSE PREDICTION PURPOSE: Application of linear‐quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi‐activation (UMA) model to fit cell survival curves over the entire dose range that allows us to calculate EQD2 for hypofractionated SBRT, SRT, SRS, and HDRB. METHODS: A unified formula of cell survival [Formula: see text] using only the extrapolation number of n and the dose slope of D(o) was derived. Coefficient of determination, R(2), relative residuals, r, and relative experimental errors, e, normalized to survival fraction at each dose point, were calculated to quantify the goodness in modeling of a survival curve. Analytical solutions for α and β, the coefficients respectively describe the linear and quadratic parts of the survival curve, as well as the α/β ratio for the LQ model and EQD2 at any fractional doses were derived for tumor cells undertaking any fractionated radiation therapy. RESULTS: Our proposed model fits survival curves of in‐vivo and in‐vitro tumor cells with R(2) > 0.97 and r < e. The predicted α, β, and α/β ratio are significantly different from their values in the LQ model. Average EQD2 of 20‐Gy SRS of glioblastomas and melanomas metastatic to the brain, 10‐Gy × 5 SBRT of the lung cancer, and 7‐Gy × 5 HDRB of endometrial and cervical carcinomas are 36.7 (24.3–48.5), 114.1 (86.6–173.1),, and 45.5 (35–52.6) Gy, different from the LQ model estimates of 50.0, 90.0, and 49.6 Gy, respectively. CONCLUSION: Our UMA model validated through many tumor cell lines can fit cell survival curves over the entire dose range within their experimental errors. The unified formula theoretically indicates a common mechanism of cell inactivation and can estimate EQD2 at all dose levels. John Wiley and Sons Inc. 2021-02-16 2021-04 /pmc/articles/PMC8248130/ /pubmed/33590493 http://dx.doi.org/10.1002/mp.14690 Text en © 2021 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle BIOLOGICAL PHYSICS AND RESPONSE PREDICTION
Li, Shidong
Miyamoto, Curtis
Wang, Bin
Giaddui, Tawfik
Micaily, Bizhan
Hollander, Andrew
Weiss, Stephanie E.
Weaver, Michael
A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title_full A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title_fullStr A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title_full_unstemmed A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title_short A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
title_sort unified multi‐activation (uma) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (sbrt), high dose rate brachytherapy (hdrb), and stereotactic radiosurgery (srs)
topic BIOLOGICAL PHYSICS AND RESPONSE PREDICTION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248130/
https://www.ncbi.nlm.nih.gov/pubmed/33590493
http://dx.doi.org/10.1002/mp.14690
work_keys_str_mv AT lishidong aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT miyamotocurtis aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT wangbin aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT giadduitawfik aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT micailybizhan aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT hollanderandrew aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT weissstephaniee aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT weavermichael aunifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT lishidong unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT miyamotocurtis unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT wangbin unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT giadduitawfik unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT micailybizhan unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT hollanderandrew unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT weissstephaniee unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs
AT weavermichael unifiedmultiactivationumamodelofcellsurvivalcurvesovertheentiredoserangeforcalculatingequivalentdosesinstereotacticbodyradiationtherapysbrthighdoseratebrachytherapyhdrbandstereotacticradiosurgerysrs